chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chest X-ray, Fatigue, Myalgia, Nausea
Clinical narrative: body ache; rash; UTI; tested positive; Vomiting; Nausea; Fatigue; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of URINARY TRACT INFECTION (UTI), MYALGIA (body ache), COVID-19 (tested positive), RASH (rash) and VOMITING (Vomiting) in a 91-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Nausea, COVID-19 on 22-Jan-2021 and COPD. Concomitant products included ELECTROLYTES NOS, GLUCOSE (PEDIALYTE [ELECTROLYTES NOS;GLUCOSE]) for Dehydration, ONDANSETRON (ZOFRAN [ONDANSETRON]) for Nausea, PREDNISOLONE for an unknown indication.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced COVID-19 (tested positive), VOMITING (Vomiting), NAUSEA (Nausea) and FATIGUE (Fatigue). On 25-Jan-2021, the patient experienced URINARY TRACT INFECTION (UTI). On 26-Jan-2021, the patient experienced RASH (rash). On an unknown date, the patient experienced MYALGIA (body ache). On 25-Jan-2021, VOMITING (Vomiting) outcome was unknown. On 29-Jan-2021, FATIGUE (Fatigue) outcome was unknown. On 31-Jan-2021, URINARY TRACT INFECTION (UTI) and RASH (rash) outcome was unknown. At the time of the report, MYALGIA (body ache), COVID-19 (tested positive) and NAUSEA (Nausea) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Jan-2021, Chest X-ray: no signs of pneumonia/infection. On 22-Jan-2021, SARS-CoV-2 test: positive (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient  lived on Pedialyte for 2 weeks. He had no appetite, but this helped him from getting dangerously dehydrated   Most recent FOLLOW-UP information incorporated above includes: On 23-Jul-2021: addition of lab data and medical history
Sex: M
Vaccine: COVID19
Symptoms: Rash, SARS-CoV-2 test, Urinary tract infection, Vomiting
Clinical narrative: body ache; rash; UTI; tested positive; Vomiting; Nausea; Fatigue; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of URINARY TRACT INFECTION (UTI), MYALGIA (body ache), COVID-19 (tested positive), RASH (rash) and VOMITING (Vomiting) in a 91-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Nausea, COVID-19 on 22-Jan-2021 and COPD. Concomitant products included ELECTROLYTES NOS, GLUCOSE (PEDIALYTE [ELECTROLYTES NOS;GLUCOSE]) for Dehydration, ONDANSETRON (ZOFRAN [ONDANSETRON]) for Nausea, PREDNISOLONE for an unknown indication.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced COVID-19 (tested positive), VOMITING (Vomiting), NAUSEA (Nausea) and FATIGUE (Fatigue). On 25-Jan-2021, the patient experienced URINARY TRACT INFECTION (UTI). On 26-Jan-2021, the patient experienced RASH (rash). On an unknown date, the patient experienced MYALGIA (body ache). On 25-Jan-2021, VOMITING (Vomiting) outcome was unknown. On 29-Jan-2021, FATIGUE (Fatigue) outcome was unknown. On 31-Jan-2021, URINARY TRACT INFECTION (UTI) and RASH (rash) outcome was unknown. At the time of the report, MYALGIA (body ache), COVID-19 (tested positive) and NAUSEA (Nausea) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Jan-2021, Chest X-ray: no signs of pneumonia/infection. On 22-Jan-2021, SARS-CoV-2 test: positive (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient  lived on Pedialyte for 2 weeks. He had no appetite, but this helped him from getting dangerously dehydrated   Most recent FOLLOW-UP information incorporated above includes: On 23-Jul-2021: addition of lab data and medical history
Sex: U
Vaccine: COVID19
Symptoms: Type IV hypersensitivity reaction
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of TYPE IV HYPERSENSITIVITY REACTION (delayed hypersensitivity) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced TYPE IV HYPERSENSITIVITY REACTION (delayed hypersensitivity). At the time of the report, TYPE IV HYPERSENSITIVITY REACTION (delayed hypersensitivity) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, Dizziness, Electrocardiogram, Heart rate, Heart rate increased
Clinical narrative: Felt dizzy; Elevated heart rate; throat felt like it was getting tight; A regulatory authority report was received from a 72-year-old  female consumer who received Moderna's COVID-19 vaccine and experienced dizziness, elevated heart rate to 151 and throat tightness.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 19-JAN-2021, prior to the onset of events, the patient received her first of two planned doses of mRNA-1273(Lot number:013L20A) intramuscularly in the right arm for prophylaxis of COVID-19 infection.  On 19-JAN-2021, 2nd day after receiving vaccine, the patient felt dizziness, elevated heart rate and tightness in throat. She went to ER for treatment.  Treatment details were not provided.  Action taken with the second dose of mRNA-1273 in response to the event was not reported.  The outcome for the events dizziness, elevated heart rate to 153 and throat tightness were not resolved at the time of report.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Throat tightness
Clinical narrative: Felt dizzy; Elevated heart rate; throat felt like it was getting tight; A regulatory authority report was received from a 72-year-old  female consumer who received Moderna's COVID-19 vaccine and experienced dizziness, elevated heart rate to 151 and throat tightness.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 19-JAN-2021, prior to the onset of events, the patient received her first of two planned doses of mRNA-1273(Lot number:013L20A) intramuscularly in the right arm for prophylaxis of COVID-19 infection.  On 19-JAN-2021, 2nd day after receiving vaccine, the patient felt dizziness, elevated heart rate and tightness in throat. She went to ER for treatment.  Treatment details were not provided.  Action taken with the second dose of mRNA-1273 in response to the event was not reported.  The outcome for the events dizziness, elevated heart rate to 153 and throat tightness were not resolved at the time of report.
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pyrexia, SARS-CoV-2 test
Clinical narrative: Sore throat; Fever; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (Sore throat) and PYREXIA (Fever) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced OROPHARYNGEAL PAIN (Sore throat) and PYREXIA (Fever). The patient was treated with AZITHROMYCIN for Adverse event, at an unspecified dose and frequency. On 13-Jan-2021, OROPHARYNGEAL PAIN (Sore throat) and PYREXIA (Fever) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In January 2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site swelling, Vaccination site warmth
Clinical narrative: hot to the touch; rose oval 6-7 inches; swollen; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (hot to the touch), VACCINATION SITE ERYTHEMA (rose oval 6-7 inches) and VACCINATION SITE SWELLING (swollen) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Jan-2021, the patient experienced VACCINATION SITE WARMTH (hot to the touch), VACCINATION SITE ERYTHEMA (rose oval 6-7 inches) and VACCINATION SITE SWELLING (swollen). At the time of the report, VACCINATION SITE WARMTH (hot to the touch), VACCINATION SITE ERYTHEMA (rose oval 6-7 inches) and VACCINATION SITE SWELLING (swollen) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use information was not provided  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 02-Jul-2021: Significant FU: TCR was received In that Second dose details provided, out come of event of first dose also provided.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy
Clinical narrative: exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (exposure during pregnancy) in a 31-year-old female patient (gravida 4) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     The patient's past medical history included Pregnancy (4 pregnancies).    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. Last menstrual period and estimated date of delivery were not provided. On 13-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (exposure during pregnancy). At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (exposure during pregnancy) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient's pregnancy positive test, last mensuration period date and conceptions dates were not provided.  No relevant concomitant medications were reported.   Reporter did not allow further contact; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this 31-year-old female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Maternal exposure during pregnancy
Clinical narrative: diagnosed with covid; Vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a physician and describes the occurrence of COVID-19 (diagnosed with covid) and MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for covid-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced COVID-19 (diagnosed with covid) and MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy). At the time of the report, COVID-19 (diagnosed with covid) outcome was unknown and MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, COVID-19: Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient was 6 months pregnant when she received first dose of vaccine.  No relevant concomitant medications were reported.  No treatment information was provided   Reporter did not allow further contact
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy
Clinical narrative: pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (pregnancy) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038K20A) for COVID-19 vaccination.     Concurrent medical conditions included Fibroids (She has a known fibroid).    On 22-Jan-2021 at 4:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 21-May-2021. On 22-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (pregnancy). On 22-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (pregnancy) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Estimated date of conception was on 28-Aug-2020 via invitro fertilization. Number of fetus was found to be one.  Concomitant product use was not provided by the reporter.  Treatment information was not provided.; Sender's Comments: This is a case of product exposure during pregnancy with no associated AEs for this 44-year-old female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy, Pain in extremity, Pregnancy test
Clinical narrative: Pregnant patient had first dose of vaccine administered; really sore arm; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant patient had first dose of vaccine administered) and PAIN IN EXTREMITY (really sore arm) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in November 2020. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 11-Mar-2021. On 01-Feb-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant patient had first dose of vaccine administered) and PAIN IN EXTREMITY (really sore arm). On 01-Feb-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant patient had first dose of vaccine administered) had resolved. At the time of the report, PAIN IN EXTREMITY (really sore arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Jun-2020, Pregnancy test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   At the time of this report, patient was 35 weeks pregnant.   Treatment information was not provided
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy, Ultrasound scan
Clinical narrative: Pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnant) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Ectopic pregnancy on date and Alcohol use. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 10-May-2020 and the estimated date of delivery was date. On an unknown date, the patient experienced EXPOSURE DURING PREGNANCY (Pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) during pregnancy.  At the time of the report, EXPOSURE DURING PREGNANCY (Pregnant) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Ultrasound scan: normal (normal) Normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       ON an unknown date, post vaccination. the patient reported that she experienced symptoms of exposure during pregnancy.   No treatment information was provided.  No concomitant medication was provided.   Most recent FOLLOW-UP information incorporated above includes: On 02-Feb-2021: Internal review on 24-Jun-21 resulted in updates to pregnancy details.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy
Clinical narrative: Pregnancy; This spontaneous prospective pregnancy case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History was provided by the reporter.  Concomitant products included BUDESONIDE (PULMICORT) for an unknown indication.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 03-Nov-2020 and the estimated date of delivery was 10-Aug-2021. On 03-Feb-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  thirteenth week of the pregnancy.  At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy
Clinical narrative: patient is pregnant and has already received both doses of the vaccine; This spontaneous prospective pregnancy case was reported by a physician and describes the occurrence of EXPOSURE DURING PREGNANCY (patient is pregnant and has already received both doses of the vaccine) in a 34-year-old female patient (gravida 3) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 028L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 11-Jun-2021. On 29-Dec-2020, the patient experienced EXPOSURE DURING PREGNANCY (patient is pregnant and has already received both doses of the vaccine). On 28-Jan-2021, EXPOSURE DURING PREGNANCY (patient is pregnant and has already received both doses of the vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.  No concomitant medication was provided.  The patient previously had two miscarriages.
Sex: F
Vaccine: COVID19
Symptoms: Maternal exposure during pregnancy, Pregnancy test
Clinical narrative: Pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 Vaccination.     Concurrent medical conditions included Migraine. Concomitant products included OLANZAPINE (OLAFID), 1 mg aspirine, progesterone injections and PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE] for an unknown indication.    On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 11-Sep-2020 and the estimated date of delivery was 18-Jun-2021. On 30-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twentieth week of the pregnancy.  At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In October 2020, Pregnancy test: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: soreness in arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (soreness in arm) in an 82-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (soreness in arm). At the time of the report, VACCINATION SITE PAIN (soreness in arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  No concomitant medication was provided.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: tested positive for COVID-19; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (tested positive for COVID-19) in a 28-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Jan-2021, the patient experienced COVID-19 (tested positive for COVID-19). At the time of the report, COVID-19 (tested positive for COVID-19) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.  No concomitant medication was provided.
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pyrexia, Vaccination site pain
Clinical narrative: low grade temperature; Arm sore for about five minutes where she had the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (low grade temperature) and VACCINATION SITE PAIN (Arm sore for about five minutes where she had the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.  On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 20-Jan-2021, the patient experienced PYREXIA (low grade temperature) and VACCINATION SITE PAIN (Arm sore for about five minutes where she had the vaccine).   On 20-Jan-2021, VACCINATION SITE PAIN (Arm sore for about five minutes where she had the vaccine) had resolved. At the time of the report, PYREXIA (low grade temperature) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-Jan-2021, Body temperature: 99.9 (High) F (Fahrenheit).   The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Concomitant product use was not provided by the reporter. No treatment information was provided. Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vomiting
Clinical narrative: nausea; vomiting; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (nausea) and VOMITING (vomiting) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced NAUSEA (nausea) and VOMITING (vomiting). At the time of the report, NAUSEA (nausea) and VOMITING (vomiting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were provided No Treatment information provided; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site pruritus, Vaccination site rash
Clinical narrative: injection site itching; had 3x3 inch rash; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (injection site itching), VACCINATION SITE PAIN (sore arm) and VACCINATION SITE RASH (had 3x3 inch rash) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jan-2021, the patient experienced VACCINATION SITE PAIN (sore arm). On 19-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (injection site itching) and VACCINATION SITE RASH (had 3x3 inch rash). At the time of the report, VACCINATION SITE PRURITUS (injection site itching) and VACCINATION SITE RASH (had 3x3 inch rash) had not resolved and VACCINATION SITE PAIN (sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant Concomitant medications were reported. patient reported using diphenhydramine lotion to treat her symptoms
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Eye irritation, Headache, Rhinorrhoea
Clinical narrative: Headache; Chills; Runny nose; Burining eyes; Dizziness; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of HEADACHE (Headache), CHILLS (Chills), RHINORRHOEA (Runny nose), EYE IRRITATION (Burining eyes) and DIZZINESS (Dizziness) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), DICLOFENAC POTASSIUM (VOLTAREN ACTI), ESCITALOPRAM OXALATE (LEXAPRO), CARBAMAZEPINE (TEGRETOL), BISOPROLOL FUMARATE (BISOPROLOL FUMERATE) and CLONAZEPAM (CLONAPIN) for an unknown indication.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced HEADACHE (Headache), CHILLS (Chills), RHINORRHOEA (Runny nose), EYE IRRITATION (Burining eyes) and DIZZINESS (Dizziness). At the time of the report, HEADACHE (Headache), CHILLS (Chills), RHINORRHOEA (Runny nose), EYE IRRITATION (Burining eyes) and DIZZINESS (Dizziness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient's physician instructed them to take meclizine for the treatment of the events and it has been helping.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pain, Pyrexia
Clinical narrative: This spontaneous case was reported by a patient and describes the occurrence of PAIN (body aches) and PYREXIA (fever (100.5 °F)) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029K20A) for COVID-19 vaccination. No Medical History information was reported. On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Jan-2021, the patient experienced PAIN (body aches) and PYREXIA (fever (100.5 °F)). At the time of the report, PAIN (body aches) and PYREXIA (fever (100.5 °F)) had not resolved. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 21-Jan-2021, Body temperature: 100.5 degree farenheit High. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No concomitant medications were reported. The patient had not taken any treatments yet, but plans to take Tylenol to mitigate the symptoms.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Anal pruritus, Vomiting, Vulvovaginal pruritus
Clinical narrative: itching down there (vaginal area); itching anus; vomiting; This spontaneous case was reported by a patient and describes the occurrence of VULVOVAGINAL PRURITUS (itching down there (vaginal area)), ANAL PRURITUS (itching anus) and VOMITING (vomiting) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced VULVOVAGINAL PRURITUS (itching down there (vaginal area)), ANAL PRURITUS (itching anus) and VOMITING (vomiting). On 18-Jan-2021, VOMITING (vomiting) had resolved. At the time of the report, VULVOVAGINAL PRURITUS (itching down there (vaginal area)) was resolving and ANAL PRURITUS (itching anus) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   The patient took pH balance cream (RepHresh vaginal cream), probiotic, and Clotrimazole cream for treatment of the events.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site reaction, Injection site warmth
Clinical narrative: warm; Injection site reaction; itchy; tender and Painful; redness; This spontaneous case was reported by a pharmacist and describes the occurrence of INJECTION SITE WARMTH (warm), INJECTION SITE REACTION (Injection site reaction), INJECTION SITE PRURITUS (itchy), INJECTION SITE PAIN (tender and Painful) and INJECTION SITE ERYTHEMA (redness) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Dec-2020, the patient experienced INJECTION SITE WARMTH (warm), INJECTION SITE REACTION (Injection site reaction), INJECTION SITE PRURITUS (itchy), INJECTION SITE PAIN (tender and Painful) and INJECTION SITE ERYTHEMA (redness). At the time of the report, INJECTION SITE WARMTH (warm), INJECTION SITE REACTION (Injection site reaction), INJECTION SITE PRURITUS (itchy), INJECTION SITE PAIN (tender and Painful) and INJECTION SITE ERYTHEMA (redness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.   The patient went to see her physician, who gave her a topical steroid and oral Benadryl. Their symptoms resolved within 72-96 hours of vaccination.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pruritus, Eye swelling, Hypersensitivity, Lacrimation increased
Clinical narrative: Swollen eyes; itchy eyes; watery eyes; allergic reaction; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of EYE SWELLING (Swollen eyes), EYE PRURITUS (itchy eyes), LACRIMATION INCREASED (watery eyes) and HYPERSENSITIVITY (allergic reaction) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 02L20A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy to nuts (Allergy to Brazilian nuts), Allergy to nuts (Allergy to Walnuts) and Fruit allergy (Allergy to Kiwi).    On 12-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced EYE SWELLING (Swollen eyes), EYE PRURITUS (itchy eyes), LACRIMATION INCREASED (watery eyes) and HYPERSENSITIVITY (allergic reaction). At the time of the report, EYE SWELLING (Swollen eyes), EYE PRURITUS (itchy eyes), LACRIMATION INCREASED (watery eyes) and HYPERSENSITIVITY (allergic reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   The patient stated that on 11-JAN-2021 she used a collagen fill face mask and that her physician doesn't know if the vaccine or the face mask caused the reaction. Her physician gave her prednisone and Benadryl for the allergic reaction.
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Injection site pain
Clinical narrative: diarrhea; sore arm at the site of injection; This spontaneous case was reported by a patient and describes the occurrence of DIARRHOEA (diarrhea) and INJECTION SITE PAIN (sore arm at the site of injection) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced DIARRHOEA (diarrhea) and INJECTION SITE PAIN (sore arm at the site of injection). The patient was treated with DIPHENOXYLATE for Diarrhea, at an unspecified dose and frequency and BISMUTH SUBSALICYLATE (PEPTO-BISMOL) at an unspecified dose and frequency. On 17-Jan-2021, INJECTION SITE PAIN (sore arm at the site of injection) had resolved. At the time of the report, DIARRHOEA (diarrhea) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.; Sender's Comments: Very limited information regarding this events has been provided at this time. Further information has been requested. Company assessed the events to be unlikely related to company product.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Pain in extremity
Clinical narrative: arm was red; arm tenderness; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (arm tenderness) and INJECTION SITE ERYTHEMA (arm was red) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jan-2021, the patient experienced PAIN IN EXTREMITY (arm tenderness). On 20-Jan-2021, the patient experienced INJECTION SITE ERYTHEMA (arm was red). On 10-Jan-2021, PAIN IN EXTREMITY (arm tenderness) had resolved. At the time of the report, INJECTION SITE ERYTHEMA (arm was red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pruritus, Vaccination site rash
Clinical narrative: Injection site started to feel itchy; Small round rash; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE PRURITUS (Injection site started to feel itchy) and VACCINATION SITE RASH (Small round rash) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (Allergies to sulfa), Allergy to nuts (Allergies to walnuts) and Asthma.    On 04-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (Injection site started to feel itchy) and VACCINATION SITE RASH (Small round rash). At the time of the report, VACCINATION SITE PRURITUS (Injection site started to feel itchy) and VACCINATION SITE RASH (Small round rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications include Qvar inhaler.   The patient took Benadryl, but didn't have any relief. They then used a Benadryl cream, which helped with symptoms.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Hyperhidrosis, Oropharyngeal pain, Pain in extremity, Thirst
Clinical narrative: Sore throat; Fatigue; A little pain in the arm; A bit more thirsty than normal; A bit more hand sweating than normal; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (A little pain in the arm), THIRST (A bit more thirsty than normal), HYPERHIDROSIS (A bit more hand sweating than normal), OROPHARYNGEAL PAIN (Sore throat) and FATIGUE (Fatigue) in a 50-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunisation.     No Medical History information was reported.    On 20-Jan-2021 at 5:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Jan-2021, the patient experienced PAIN IN EXTREMITY (A little pain in the arm), THIRST (A bit more thirsty than normal) and HYPERHIDROSIS (A bit more hand sweating than normal). On an unknown date, the patient experienced OROPHARYNGEAL PAIN (Sore throat) and FATIGUE (Fatigue). On 21-Jan-2021, THIRST (A bit more thirsty than normal) had resolved. At the time of the report, PAIN IN EXTREMITY (A little pain in the arm), HYPERHIDROSIS (A bit more hand sweating than normal), OROPHARYNGEAL PAIN (Sore throat) and FATIGUE (Fatigue) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.   The patient drank a bottle of water to quench his thirst, but no other treatment information was provided.    Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 15-Apr-2021: New information included the additional events of sore throat and fatigue, as well as the outcomes of the previously reported events.
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Vaccination complication
Clinical narrative: symptoms like she had when she had corona itself; arm was really sore; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (arm was really sore) and VACCINATION COMPLICATION (symptoms like she had when she had corona itself) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included 2019 novel coronavirus infection in December 2020.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jan-2021, the patient experienced PAIN IN EXTREMITY (arm was really sore). On 16-Jan-2021, the patient experienced VACCINATION COMPLICATION (symptoms like she had when she had corona itself). At the time of the report, PAIN IN EXTREMITY (arm was really sore) and VACCINATION COMPLICATION (symptoms like she had when she had corona itself) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: itching; location of the shot got swollen; it is burning; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PRURITUS (itching), VACCINATION SITE SWELLING (location of the shot got swollen) and VACCINATION SITE PAIN (it is burning) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (itching), VACCINATION SITE SWELLING (location of the shot got swollen) and VACCINATION SITE PAIN (it is burning). At the time of the report, VACCINATION SITE PRURITUS (itching), VACCINATION SITE SWELLING (location of the shot got swollen) and VACCINATION SITE PAIN (it is burning) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Cough, Pyrexia, Rhinorrhoea
Clinical narrative: cough; sniffles; slight fever; Loss of taste; This spontaneous case was reported by a patient and describes the occurrence of COUGH (cough), RHINORRHOEA (sniffles), PYREXIA (slight fever) and AGEUSIA (Loss of taste) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COUGH (cough), RHINORRHOEA (sniffles), PYREXIA (slight fever) and AGEUSIA (Loss of taste). At the time of the report, COUGH (cough), RHINORRHOEA (sniffles), PYREXIA (slight fever) and AGEUSIA (Loss of taste) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 04-Apr-2021: New information included the additional event of loss of taste.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy, Ultrasound abdomen
Clinical narrative: Pregnancy; This spontaneous prospective pregnancy case was reported by a patient and describes the occurrence of EXPOSURE DURING PREGNANCY (Pregnancy) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 17-Oct-2020 and the estimated date of delivery was date. On an unknown date, the patient experienced EXPOSURE DURING PREGNANCY (Pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) during pregnancy.  At the time of the report, EXPOSURE DURING PREGNANCY (Pregnancy) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Dec-2020, Ultrasound abdomen: normal 11 weeks.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria, Vaccination site pain
Clinical narrative: hives on thigh, hand and abdomen; sore arm; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (sore arm) and URTICARIA (hives on thigh, hand and abdomen) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032K20A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced VACCINATION SITE PAIN (sore arm). On 15-Jan-2021, the patient experienced URTICARIA (hives on thigh, hand and abdomen). At the time of the report, VACCINATION SITE PAIN (sore arm) and URTICARIA (hives on thigh, hand and abdomen) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   The patient took Benadryl and Aleve to try and relieve her symptoms.
Age: 44.0
Sex: U
Vaccine: COVID19
Symptoms: Nausea, Pain, Poor quality sleep
Clinical narrative: poor sleep; nausea; pain; This spontaneous case was reported by a patient and describes the occurrence of POOR QUALITY SLEEP (poor sleep), PAIN (pain) and NAUSEA (nausea) in a 44-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L02A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jan-2021, the patient experienced PAIN (pain). On 20-Jan-2021, the patient experienced POOR QUALITY SLEEP (poor sleep) and NAUSEA (nausea). At the time of the report, POOR QUALITY SLEEP (poor sleep), PAIN (pain) and NAUSEA (nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.    Reporter did not allow further contact
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: itching; This spontaneous case was reported by a patient and describes the occurrence of PRURITUS (itching) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Allergic reaction (Hives and itching). Concomitant products included PREDNISONE from an unknown date to 18-Jan-2021 for Allergic reaction.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRURITUS (itching). At the time of the report, PRURITUS (itching) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient's concomitant medications included unspecified blood pressure and cholesterol medications.   The patient is taking Allegra for treatment of the events.